How Bristol Myers Squibb Is Accelerating Drug...

What if one AI brain could run every robot on the planet—a humanoid, a warehouse arm, and a dog-like inspection bot—all at once? That's not a thought experiment. That's what Skild AI is building right now. Deepak Pathak (CEO and Co-Founder) and Abhinav Gupta (President and Co-Fou ...  Show more

What happens when you combine AI with quantum computing? NVIDIA's Nic Harrigan joins the AI Podcast to break down the state of quantum, explain why error correction is the pivotal challenge, and reveal how NVIDIA Ising—the world's first open AI model family for quantum—is changin ...  Show more

Can AI compress the years long research time of a PhD into seconds? Research scientist Max Jaderberg explores how “AI analogs” simulate real-world lab work with staggering speed and scale, unlocking new insights on protein folding and drug discovery. Drawing on his experience wor ...  Show more

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the centra ...  Show more

GSK’s Chief Digital and Technology Officer Shobie Ramakrishnan discusses how the company is leveraging AI and data models for vaccine development and drug discovery in this episode of Bloomberg Intelligence’s Tech Disruptors podcast. BI’s Health-Care Analyst Sam Fazeli and Techno ...  Show more

In this episode of NEJM AI Grand Rounds, hosts Raj Manrai and Andy Beam interview Dr. David Ouyang, a cardiologist and AI researcher at Cedars-Sinai Medical Center. The conversation explores Ouyang’s journey from ...